GSK, Novartis, Oryzon, Cellzome and Epizyme to present at The Epigenetics Congress
- Written by: Pitch Engine
Dr. Prinjha currently leads GSK's Epinova Epigenetics DPU and is co-chair of the GSK Biology Council. Prior to this he led the Target Progression department with responsibilities for target selection, validation and epigenetic compound characterisation along with coordinating academic collaborations. He joined Epinova from the II-virtual group which was responsible for implementing the externalisation and portfolio diversification strategy of the Therapy Area.
- Drugging the epigenome, entering the clinical phase
- BET bromodomain inhibitors and their emerging pharmacology
- Novel probes and their pharmacology across the “bromonome”, the next best BETs
|
|
If you would like to meet Dr. Prinjha and many other such epigenetic experts, sign up for the congress today.
I look forward to welcoming you at the congress.
Best regards,
MnM Conferences
P.S : Please forward this to any colleagues who you feel may be interested in the congress.
Authors: Pitch Engine
Read more http://www.pitchengine.com/pitches/6e7b504d-6de6-4c5f-bbf7-384c687bbcdf
Daily Bulletin
